Biogen And Eisai's Aducanumab: All That Glitters Is Not Gold

|
About: Biogen Inc. (BIIB), ESALF
by: Lane Simonian
This article is exclusive for subscribers.
Lane Simonian
Biotech, alternative energy
Summary

Aducanumab appears to have little effect on Alzheimer's disease progression in non-APOE4 carriers.

Aducanumab does slow down the rate of decline in APOE4 carriers during the early stages of Alzheimer's disease.

Since APOE4 carriers progress more rapidly during the early stages of Alzheimer's disesae, what aducanumab does is make APOE4 carriers decline at a rate similar to non-carriers.

Other anti-amyloid antibodies that are more effective at removing amyloid oligomers may help APOE4 carriers even more. Strong antioxidants are likely more effective yet.

The relative lack of efficacy and the existence of better alternatives make Biogen a less than stellar investment option.

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are doing their best to get FDA approval for their Alzheimer's drug aducanumab. However, a closer look at the numbers demonstrates the limited effectiveness of the